Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.
First author：Jinquan Cai
Corresponding author：Yongli Li, Tao Jiang,Chuanlu Jiang
essential_information
- Person in charge：Jinquan Cai
- Data Sources： OTHERS
- Number of papers：OTHERS20190466
- Published time：2016-09-06
2016-09-06
Published articles
Journal：Oncoscience
Publication type: Research Article
IF(IF): NA
PMID: 27713914 Link To Pubmed Full text Download
Background And Purpose
Method
In this study, we detected ATRX, IDH1-R132H and Ki-67 by immunohistochemistry and observed the association of IDH1-R132H with ATRX and Ki-67 expression.
Conclusion
The new model demonstrated a remarkable separation of the progression interval in the three molecular subgroups and the distribution of patients' age in the A1-A2-A3 model was also significant different. This model will aid predicting the overall survival and progressive time of astrocytic tumors' patients.
Main results
There was a strong association between ATRX loss and IDH1-R132H (p<0.0001). However, Ki-67 high expression restricted in the tumors with IDH1-R132H negative (p=0.0129). Patients with IDH1-R132H positive or ATRX loss astrocytic tumors had a longer progressive- free survival (p<0.0001, p=0.0044, respectively). High Ki-67 expression was associated with shorter PFS in patients with astrocytic tumors (p=0.002). Then we characterized three prognostic subgroups of astrocytic tumors (referred to as A1, A2 and A3).